Recently Expired Drugs

1. Admelog Solostar patent expiration

ADMELOG SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI-AVENTIS US Pen-type injector
Apr, 2025

(9 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 11, 2020

Drugs and Companies using INSULIN LISPRO ingredient

Market Authorisation Date: 11 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ADMELOG SOLOSTAR family patents

Family Patents

2. Ampyra patent expiration

AMPYRA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440703 MERZ Methods of using sustained release aminopyridine compositions
Apr, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2015
Orphan Drug Exclusivity(ODE) Jan 22, 2017

Drugs and Companies using DALFAMPRIDINE ingredient

NCE-1 date: 22 January, 2014

Market Authorisation Date: 22 January, 2010

Treatment: Improvement of walking in patients with multiple sclerosis (ms)

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage

AMPYRA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Apidra Solostar patent expiration

APIDRA SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(9 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 16 April, 2004

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

APIDRA SOLOSTAR family patents

Family Patents

4. Bydureon patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON family patents

Family Patents

5. Bydureon Bcise patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2020
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; Improving glycemic control in patients 10 years ...

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

6. Bydureon Pen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet ...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON PEN family patents

Family Patents

7. Cabenuva Kit patent expiration

CABENUVA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(18 hours ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

CABENUVA KIT family patents

Family Patents

8. Complera patent expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(18 hours ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 20, 2016
New Patient Population(NPP) Dec 13, 2016

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

9. Contrave patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7375111 NALPROPION Compositions for affecting weight loss
Mar, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

10. Edurant patent expiration

EDURANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(18 hours ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 20, 2016
New Patient Population(NPP) Aug 26, 2018
M(M-223) Feb 01, 2021

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 20 May, 2011

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy

Dosage: TABLET

More Information on Dosage

EDURANT family patents

Family Patents

11. Edurant Ped patent expiration

EDURANT PED's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(18 hours ago)




Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 March, 2024

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...

Dosage: TABLET, FOR SUSPENSION

More Information on Dosage

EDURANT PED family patents

Family Patents

12. Farxiga patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(8 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

13. Forteo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7517334 LILLY Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
Mar, 2025

(27 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-602) Jul 22, 2012
M(M-302) Nov 16, 2023

Drugs and Companies using TERIPARATIDE ingredient

Market Authorisation Date: 25 June, 2008

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of FORTEO before it's drug patent expiration?
More Information on Dosage

FORTEO family patents

Family Patents

14. Glumetza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7780987 SANTARUS INC Controlled release dosage forms
Mar, 2025

(29 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323692 SANTARUS INC Controlled release dosage forms
Mar, 2025

(29 days ago)




Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 03 June, 2005

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of GLUMETZA before it's drug patent expiration?
More Information on Dosage

GLUMETZA family patents

Family Patents

15. Horizant patent expiration

HORIZANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6818787 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(15 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-652) Jun 06, 2015
New Chemical Entity Exclusivity(NCE) Apr 06, 2016
Orphan Drug Exclusivity(ODE) Jun 06, 2019
Orphan Drug Exclusivity(ODE-25) Jun 06, 2019

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 13 December, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage

HORIZANT family patents

Family Patents

16. Invokamet patent expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(10 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021
New Patient Population(NPP) Dec 18, 2027
Pediatric Exclusivity(PED) Jun 18, 2028

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 19 June, 2027

Market Authorisation Date: 08 August, 2014

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

17. Invokamet Xr patent expiration

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(10 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
New Indication(I-788) Oct 29, 2021
New Patient Population(NPP) Dec 18, 2027
Pediatric Exclusivity(PED) Jun 18, 2028

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 19 June, 2027

Market Authorisation Date: 20 September, 2016

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

18. Invokana patent expiration

INVOKANA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(10 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-733) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021
New Indication(I-809) Sep 27, 2022
New Patient Population(NPP) Dec 18, 2027
Pediatric Exclusivity(PED) Jun 18, 2028

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 19 June, 2027

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET

How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage

INVOKANA family patents

Family Patents

19. Juluca patent expiration

JULUCA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(18 hours ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Combination(NC) Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage

JULUCA family patents

Family Patents

20. Kyprolis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8207125 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(7 days ago)

US7232818 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(7 days ago)

US8207297 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(7 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207127 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(7 days ago)

US8129346 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(7 days ago)

US7491704 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(7 days ago)

US8207126 ONYX PHARMS AMGEN Compounds for enzyme inhibition
Apr, 2025

(7 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2017
New Indication(I-712) Jul 24, 2018
New Indication(I-722) Jan 21, 2019
New Indication(I-723) Jan 21, 2019
Orphan Drug Exclusivity(ODE) Jul 20, 2019
Orphan Drug Exclusivity(ODE-27) Jul 20, 2019
New Dosing Schedule(D-172) Sep 28, 2021
New Indication(I-842) Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

NCE-1 date: 20 July, 2016

Market Authorisation Date: 07 June, 2018

Treatment: Kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Kyp...

Dosage: POWDER

How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage

KYPROLIS family patents

Family Patents

21. Lantus Solostar patent expiration

LANTUS SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI AVENTIS US Pen-type injector
Apr, 2025

(9 days ago)




Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 27 April, 2007

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LANTUS SOLOSTAR family patents

Family Patents

22. Odefsey patent expiration

ODEFSEY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(18 hours ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-206) Aug 21, 2020
M(M-207) Aug 21, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

23. Oraverse patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7575757 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Apr, 2025

(18 hours ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Mar 18, 2019

Drugs and Companies using PHENTOLAMINE MESYLATE ingredient

Market Authorisation Date: 09 May, 2008

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

ORAVERSE family patents

Family Patents

24. Oxycontin patent expiration

OXYCONTIN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(22 days ago)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(22 days ago)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(22 days ago)

US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(22 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(22 days ago)

US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(22 days ago)

US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(22 days ago)

US12060361 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(22 days ago)

US7776314 PURDUE PHARMA LP Abuse-proofed dosage system
Apr, 2025

(2 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-153) Apr 16, 2016
New Patient Population(NPP) Aug 13, 2018

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 December, 1995

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

OXYCONTIN family patents

Family Patents

25. Protonix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550153

(Pediatric)

WYETH PHARMS Pantoprazole multiparticulate formulations
Mar, 2025

(22 days ago)

US7553498

(Pediatric)

WYETH PHARMS Pantoprazole multiparticulate formulations
Mar, 2025

(22 days ago)

US7838027

(Pediatric)

WYETH PHARMS Pantoprazole multiparticulate formulations
Mar, 2025

(22 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-614) Nov 12, 2012
M(M-54) Nov 12, 2012
Pediatric Exclusivity(PED) May 12, 2013

Drugs and Companies using PANTOPRAZOLE SODIUM ingredient

Market Authorisation Date: 14 November, 2007

Treatment: NA

Dosage: FOR SUSPENSION, DELAYED RELEASE

How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage

PROTONIX family patents

Family Patents

26. Soliqua 100/33 patent expiration

SOLIQUA 100/33 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI-AVENTIS US Pen-type injector
Apr, 2025

(9 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SOLIQUA 100/33 family patents

Family Patents

27. Symtuza patent expiration

SYMTUZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 JANSSEN PRODS Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(4 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Combination(NC) Jul 17, 2021

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 17 July, 2018

Treatment: NA

Dosage: TABLET

How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage

SYMTUZA family patents

Family Patents

28. Targiniq patent expiration

TARGINIQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(22 days ago)

US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(22 days ago)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(22 days ago)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(22 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(22 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2017

Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 July, 2014

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

TARGINIQ family patents

Family Patents

29. Tegsedi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8101743 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2025

(20 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2023
Orphan Drug Exclusivity(ODE-212) Oct 05, 2025

Drugs and Companies using INOTERSEN SODIUM ingredient

NCE-1 date: 05 October, 2022

Market Authorisation Date: 05 October, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TEGSEDI family patents

Family Patents

30. Toujeo Max Solostar patent expiration

TOUJEO MAX SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI US SERVICES Pen-type injector
Apr, 2025

(9 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Nov 26, 2022

Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TOUJEO MAX SOLOSTAR family patents

Family Patents

31. Toujeo Solostar patent expiration

TOUJEO SOLOSTAR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679069 SANOFI US SERVICES Pen-type injector
Apr, 2025

(9 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 25, 2018
New Patient Population(NPP) Nov 26, 2022

Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

TOUJEO SOLOSTAR family patents

Family Patents

32. Wainua (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8101743 ASTRAZENECA AB Modulation of transthyretin expression
Apr, 2025

(20 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2028
Orphan Drug Exclusivity(ODE-461) Dec 21, 2030

Drugs and Companies using EPLONTERSEN SODIUM ingredient

NCE-1 date: 22 December, 2027

Market Authorisation Date: 21 December, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

WAINUA (AUTOINJECTOR) family patents

Family Patents

33. Xtampza Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7771707 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(28 days ago)

US8449909 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(28 days ago)

US7399488 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Mar, 2025

(28 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 26, 2019

Drugs and Companies using OXYCODONE ingredient

Market Authorisation Date: 26 April, 2016

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of XTAMPZA ER before it's drug patent expiration?
More Information on Dosage

XTAMPZA ER family patents

Family Patents